stock price | GenomeWeb

stock price

The GenomeWeb Index, which fell nearly 9 percent in October, rebounded to a 1 percent gain in November, but still underperformed the Dow and Nasdaq.

The GenomeWeb Index fell nearly 9 percent in October, doubling back on September's 5 percent gain and underperforming the Dow and the Nasdaq.

The GenomeWeb Index gained more than 5 percent in September, after falling more than 2 percent in August, and outperformed the Nasdaq Biotechnology Index.

Coming off a nearly 9 percent rise in July, the GenomeWeb Index fell more than 2 percent in August, mimicking the Nasdaq Biotechnology Index, which fell 3 percent.

A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.

The GenomeWeb Index fell half a percent in June, underperforming the Dow Jones Industrial Average, but far outpacing the Nasdaq and Nasdaq Biotech Index.

The GenomeWeb Index rose 4 percent in May, in line with the Nasdaq and the Nasdaq Biotech Index, and outperforming the Dow Jones Industrial Average.

The GenomeWeb Index fell 1 percent in April, outperforming the Nasdaq, but falling significantly short of the performance of the Nasdaq Biotech Index.

The GenomeWeb Index rose more than 6 percent in March, in line with the Dow and the Nasdaq, and significantly outperforming the Nasdaq Biotech Index.

The GenomeWeb Index was flat in February month over month, in line with the Dow but outperforming the Nasdaq and the Nasdaq Biotech Index.

Pages

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.